PUBLICATION

Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish

Authors
Yan, C., Brunson, D.C., Tang, Q., Do, D., Iftimia, N.A., Moore, J.C., Hayes, M.N., Welker, A.M., Garcia, E.G., Dubash, T.D., Hong, X., Drapkin, B.J., Myers, D.T., Phat, S., Volorio, A., Marvin, D.L., Ligorio, M., Dershowitz, L., McCarthy, K.M., Karabacak, M.N., Fletcher, J.A., Sgroi, D.C., Iafrate, J.A., Maheswaran, S., Dyson, N.J., Haber, D.A., Rawls, J.F., Langenau, D.M.
ID
ZDB-PUB-190430-2
Date
2019
Source
Cell   177(7): 1903-1914.e14 (Journal)
Registered Authors
Hayes, Madeline, Langenau, David, Moore, John, Rawls, John F., Tang, Qin
Keywords
SCID, breast cancer, il2rg, immune deficient, melanoma, prkdc, rhabdomyosarcoma, xenograft, zebrafish
MeSH Terms
  • Animals
  • Animals, Genetically Modified/genetics
  • Animals, Genetically Modified/immunology
  • Animals, Genetically Modified/metabolism*
  • Antineoplastic Combined Chemotherapy Protocols/pharmacology*
  • Female
  • Heterografts
  • Humans
  • K562 Cells
  • Male
  • Muscle Neoplasms*/drug therapy
  • Muscle Neoplasms*/immunology
  • Muscle Neoplasms*/metabolism
  • Muscle Neoplasms*/pathology
  • Neoplasm Transplantation
  • Phthalazines/pharmacology
  • Piperazines/pharmacology
  • Rhabdomyosarcoma*/drug therapy
  • Rhabdomyosarcoma*/immunology
  • Rhabdomyosarcoma*/metabolism
  • Rhabdomyosarcoma*/pathology
  • Temozolomide/pharmacology
  • Xenograft Model Antitumor Assays
  • Zebrafish/genetics
  • Zebrafish/immunology
  • Zebrafish/metabolism*
PubMed
31031007 Full text @ Cell
Abstract
Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an optically-clear prkdc-/-, il2rga-/- zebrafish that lacks adaptive and natural killer immune cells, can engraft a wide array of human cancers at 37°C, and permits the dynamic visualization of single engrafted cells. For example, photoconversion cell-lineage tracing identified migratory and proliferative cell states in human rhabdomyosarcoma, a pediatric cancer of muscle. Additional experiments identified the preclinical efficacy of combination olaparib PARP inhibitor and temozolomide DNA-damaging agent as an effective therapy for rhabdomyosarcoma and visualized therapeutic responses using a four-color FUCCI cell-cycle fluorescent reporter. These experiments identified that combination treatment arrested rhabdomyosarcoma cells in the G2 cell cycle prior to induction of apoptosis. Finally, patient-derived xenografts could be engrafted into our model, opening new avenues for developing personalized therapeutic approaches in the future.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping